title: Inhaled iloprost controls pulmonary hypertension after cardiopulmonary bypass.
abstract: OBJECTIVE
  Severe pulmonary hypertension (PH) is a major cause of right ventricular (RV) dysfunction. Various iv vasodilator modalities have been used with limited results because of lack of pulmonary selectivity. The aim of the present controlled study was to evaluate the efficacy of inhaled iloprost, a synthetic prostacyclin analogue, in patients with elevated pulmonary vascular resistance (PVR) immediately after separation from cardiopulmonary bypass (CPB).
  
  
  METHODS
  Twelve patients with persistent PH after discontinuation of CPB were included in the study. In all patients standard hemodynamic monitoring was used. Inhaled iloprost was administered via nebulized aerosol at a cumulative dose of 0.2 micro g*kg(-1) for a total duration of 20 min. Complete sets of hemodynamic measurements were performed before inhalation (baseline), during and after cessation of the inhalation period. Echocardiographic monitoring of RV function was also used.
  
  
  RESULTS
  Inhaled iloprost induced a reduction in the transpulmonary gradient at the end of the inhalation period in comparison to baseline (9.33 +/- 3.83 mmHg vs 17.09 +/- 6.41 mmHg, P < 0.05). The mean pulmonary artery pressure to systemic artery pressure ratio decreased over this period (0.28 +/- 0.08 vs 0.45 +/- 0.17, P < 0.05). A statistically significant decrease of the PVR to systemic vascular resistance ratio was also observed (0.15 +/- 0.05 vs 0.21 +/- 0.05, P < 0.05). Improved indices of RV function were observed in echocardiographic monitoring.
  
  
  CONCLUSIONS
  Inhaled iloprost appears to be a selective pulmonary vasodilator and may be effective in the initial treatment of PH and the improvement of RV performance in the perioperative setting.
authors.affiliation: Department of Anesthesiology, and the 1 Cardiosurgery Division, Onassis Cardiac Surgery Centre, Athens, Greece. kthcodoraki@hotmail.com
authors.forename: Kassiani
authors.initials: K
authors.lastname: Theodoraki
authors.forename: Panagiota
authors.initials: P
authors.lastname: Rellia
authors.forename: Apostolos
authors.initials: A
authors.lastname: Thanopoulos
authors.forename: Loukas
authors.initials: L
authors.lastname: Tsourelis
authors.forename: Dimitrios
authors.initials: D
authors.lastname: Zarkalis
authors.forename: Petros
authors.initials: P
authors.lastname: Sfyrakis
authors.forename: Theophani
authors.initials: T
authors.lastname: Antoniou
mesh_terms: D000280:Administration, Inhalation; D000368:Aged; D002315:Cardiopulmonary Bypass / Q000009:adverse effects*; D004562:Electrocardiography; D005260:Female; D006439:Hemodynamics / Q000187:drug effects / Q000502:physiology; D006801:Humans; D006976:Hypertension, Pulmonary / Q000188:drug therapy* / Q000209:etiology*; D016285:Iloprost / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D016343:Monitoring, Intraoperative; D011183:Postoperative Complications / Q000188:drug therapy*; D011652:Pulmonary Circulation / Q000187:drug effects / Q000502:physiology; D014655:Vascular Resistance / Q000502:physiology; D014665:Vasodilator Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D016278:Ventricular Function, Right
chemical_list: D014665:Vasodilator Agents; D016285:Iloprost